News Release

Combining math and medicine to treat leukemia

Peer-Reviewed Publication

PLOS

Researchers have produced a mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML). The model takes into account the natural anti-leukemia response in patients that are treated with the drug imatinib. This approach provides insights on how to improve the treatment of leukemia patients. Details are published June 20th in the open-access journal PLoS Computational Biology.

The study represents a collaboration between researchers at the University of Maryland, Stanford University, and École Supérieure d'Électricité (Gif-sur-Yvette, France).

"By combining novel biological data and mathematical modeling, we found rules for designing adaptive treatments for each specific patient," said Professor Doron Levy. "Give me a thousand patients and, with this mathematical model, I can give you a thousand different customized treatment plans."

The study by Levy, Professor Peter P. Lee and Dr. Peter S. Kim uses data collected over four years from CML patients during imatinib therapy.

"Our results suggest that it is not only the drug that sends the leukemia into remission, it's also the natural immune response," Levy said. "After starting imatinib, the anti-leukemia immune response gradually increases. However, it begins to weaken after it reaches a peak [as the leukemia cells are greatly diminished in number]. This typically happens well into the treatment."

This provides a window for cancer cells to develop drug resistance that could render the therapy ineffective. The authors therefore recommend strengthening the immune system at this, its weakest point through "cancer vaccines" in which pre-therapy blood taken from patients is irradiated to kill active cancer cells and then introduced back to the patient.

Levy and Lee are currently conducting further studies to expand on the results of this research, which they hope will lead to the development of animal models and, eventually, clinical trials.

###

The research was funded by the American Cancer Society, the National Cancer Institute, and the National Science Foundation.

PLEASE ADD THIS LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://www.ploscompbiol.org/doi/pcbi.1000095 (link will go live on Friday, June 20)

CITATION: Kim PS, Lee PP, Levy D (2008) Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia. PLoS Comput Biol 4(6): e1000095. doi:10.1371/journal.pcbi.1000095

CONTACT:

To speak with Doron Levy, contact Ellen Ternes, 301-405-4627, eternes@umd.edu
To speak with Peter Lee, contact Krista Conger, 650-725-5371, kristac@stanford.edu


Disclaimer

This press release refers to an upcoming article in PLoS Computational Biology. The release is provided by the article authors and/or their institutions. Any opinions expressed in this release or article are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

About PLoS Computational Biology

PLoS Computational Biology (www.ploscompbiol.org) features works of exceptional significance that further our understanding of living systems at all scales through the application of computational methods. All works published in PLoS Computational Biology are open access. Everything is immediately available subject only to the condition that the original authorship and source are properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.